Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.

@article{Kirchheiner2002ImpactOC,
  title={Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.},
  author={Julia Kirchheiner and Steffen Bauer and Ingolf Meineke and Wolfgang Rohde and Verena Prang and Christian Meisel and Ivor Roots and J{\"u}rgen Brockm{\"o}ller},
  journal={Pharmacogenetics},
  year={2002},
  volume={12 2},
  pages={101-9}
}
Tolbutamide is known to be metabolized by cytochrome P450 2C9 (CYP2C9), and the effects of the CYP2C9 amino acid polymorphisms *2 (Arg144Cys) and *3 (Ile359Leu) could be important for drug treatment with tolbutamide and for use of tolbutamide as a CYP2C9 test drug. Tolbutamide pharmacokinetics and plasma insulin and glucose concentrations were studied in 23 healthy volunteers with all six combinations of the CYP2C9 alleles *1, *2 and *3, including two subjects with the combined CYP2C9*1/*1 and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 61 extracted citations

Similar Papers

Loading similar papers…